Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow

Study Overview
=================
Brief Summary
-----------------
The purpose of this study will be to compare the aqueous production suppressant to aqueous outflow drugs in terms of the response to known vascular parameters. Specifically; systemic perfusion pressure, retrobulbar blood flow and retinal microcirculation.

Detailed Description
-----------------
The purpose of this study will be to compare the aqueous production suppressant to aqueous outflow drugs in terms of the response to known vascular parameters. Specifically; systemic perfusion pressure, retrobulbar blood flow and retinal microcirculation. A comparison of perfusion pressure, retinal microcirculation utilizing Heidelberg Retinal Flowmetry and retrobulbar circulation utilizing color Doppler ultrasound imaging

Official Title
-----------------
Examination of the Effect of Aqueous Suppressant Versus Aqueous Outflow Enhancing Glaucoma Medications on Ocular Perfusion Pressure and Blood Flow: A Mechanistic Study

Conditions
-----------------
Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will meet all of the following inclusion criteria to enter the study: Age: 30 years or older. Diagnosis: confirmed open-angle glaucoma in at least one eye: glaucomatous visual field loss on Humphrey 24-2 or 10-2 perimetry glaucomatous optic disc cupping agreement between two baseline exams for reliability Best corrected visual acuity at least 20/60 in at least one eye. Prior Humphrey visual fields demonstrate acceptable reliability standards (see below). Exclusion Criteria: Extensive Humphrey visual field damage consisting of either a mean deviation (MD) < -15 decibels or a clinically determined threat to fixation in both hemifields. Evidence of exfoliation or pigment dispersion. History of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy. History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis). History or signs of intraocular trauma. Severe or potentially progressive retinal disease such as retinal degeneration, diabetic retinopathy, and retinal detachment. Any abnormality preventing reliable applanation tonometry. Current use of any ophthalmic or systemic steroid which may interfere with this investigation. Cataract surgery within the past year. Resting pulse < 50 beats per minute. Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| aqueous suppressant<br>aqueous suppressant treated | |
| aqueous outflow<br>aqueous outflow treated | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV) |  | Baseline and 6 month visits | 
| 6-month Change in Phthalmic Artery (OA) End Diastolic Velocity (EDV) |  | Baseline and 6 month visits | 
| 6-month Change in Phthalmic Artery (OA) Vascular Resistance (RI) |  | Baseline and 6 month visits | 
| 6-month Change in Central Retinal Artery (CRA) Peak Systolic Velocity (PSV) |  | Baseline and 6 month visits | 
| 6-month Change in Central Retinal Artery (CRA) End Diastolic Velocity (EDV) |  | Baseline and 6 month visits | 
| 6-month Change in Central Retinal Artery (CRA) Vascular Resistance (RI) |  | Baseline and 6 month visits | 
| 6-month Change in Ocular Perfusion Pressures (OPP) |  | Baseline and 6 month visits | 
| 2-year Change in OA PSV |  | Baseline and 24 month visits | 
| 2-year Change in OA EDV |  | Baseline and 24 month visits | 
| 2-year Change in OA RI |  | Baseline and 24 month visits | 
| 2-year Change in CRA PSV |  | Baseline and 24 month visits | 
| 2-year Change in CRA EDV |  | Baseline and 24 month visits | 
| 2-year Change in CRA RI |  | Baseline and 24 month visits | 
| 2-year Change in OPP |  | Baseline and 24 month visits | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glaucoma blood flow